Key Highlights

  • Eupraxia Pharmaceuticals shared new RESOLVE trial data for EP-104GI in eosinophilic esophagitis.
  • Moderate-to-severe odynophagia rates fell from 62% at baseline to just 25% by weeks 24-52.
  • Half of patients reported zero pain upon swallowing by the one-year mark.
  • The data underscore a significant and lasting reduction in disease-related symptom burden.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) shared a fresh look at its RESOLVE trial for EP-104GI in eosinophilic esophagitis, revealing that moderate-to-severe odynophagia rates plunged from 62% at baseline to just 25% by weeks 24 to 52.

What Happened

With half of the patients reporting zero pain upon swallowing by the one-year mark, the data underscore a significant and lasting reduction in disease-related symptom burden.

Market Reaction

The disclosed information does not include stock price or trading data for Eupraxia Pharmaceuticals following the RESOLVE trial update.

Outlook

Continued follow-up on the durability of symptom reduction observed in the RESOLVE trial is likely to remain relevant as Eupraxia Pharmaceuticals advances EP-104GI in eosinophilic esophagitis.